{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041370","form_type":"8-K","ticker":"PAVM","cik":"0001624326","company_name":"PAVmed Inc.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.824621+00:00","generated_at":"2026-06-08T02:26:32.819644+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PAVmed Q3 revenue $0.8M, net loss $0.16/share; Lucid revenue surges 392% sequentially","bullets":["Q3 2023 revenue $0.8M; GAAP net loss $17.7M ($0.16 per share), non-GAAP adjusted loss $9.7M ($0.09).","Lucid generated $783K revenue, up 392% sequentially; EsoGuard testing volumes up 17% sequentially and 137% YoY.","Cash and equivalents $26.4M at Sept 30, down from $37.2M at June 30, reflecting ongoing cash burn.","Veris Health launching next-gen Cancer Care Platform in Q4; on track for FDA 510(k) submission next year and implantable monitor in 2024.","Lucid launched EsoGuard 2.0 with enhanced performance and lower per-sample costs; clinical utility data showed 98-100% concordance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041370","json":"https://secwatch.observer/filing/0001493152-23-041370.json","markdown":"https://secwatch.observer/filing/0001493152-23-041370.md","text":"https://secwatch.observer/filing/0001493152-23-041370.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223041370/0001493152-23-041370-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1624326/000149315223041370/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:26:32.819644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}